Related Experiment Video
Updated: Jun 26, 2026
A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
Published on: May 14, 2013
The role of beta-adrenergic blocking agents in preventing sudden cardiac death
1Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor 48109-0366.
Insights
Beta-adrenergic blocking agents show promise in preventing sudden cardiac death, particularly in patients with reduced left ventricular ejection fraction. Research is ongoing to explore their efficacy, especially with new vasodilator properties.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Previous antiarrhythmic drug trials (Cardiac Arrhythmia Suppression Trial) showed limitations of encainide and flecainide in post-infarction mortality.
- Low-dose amiodarone also proved ineffective in preventing sudden cardiac death in patients with low left ventricular ejection fraction.
Purpose of the Study:
- To review existing evidence and mechanisms of beta-adrenergic blocking agents in preventing sudden cardiac death.
- To highlight the potential of beta-adrenergic blocking agents, especially in patients with low left ventricular ejection fraction.
- To introduce new investigational beta-adrenergic blocking agents with vasodilator properties for further study.
Main Methods:
- Review of previous studies on beta-adrenergic blocking agents.
- Analysis of proposed mechanisms for their efficacy in preventing sudden cardiac death.
- Consideration of emerging beta-adrenergic blocking agents with vasodilator properties.
Main Results:
- Accumulating evidence suggests potential benefit of beta-adrenergic blocking agents in preventing sudden cardiac death.
- Particular promise is noted for patients with low left ventricular ejection fraction.
- New agents with vasodilator properties offer novel therapeutic avenues.
Conclusions:
- Beta-adrenergic blocking agents represent a promising strategy for preventing sudden cardiac death.
- Further investigation is warranted, especially in high-risk populations like those with low left ventricular ejection fraction.
- Novel beta-adrenergic blocking agents may offer improved efficacy and safety profiles.
Abstract:
The failure of encainide and flecainide to reduce mortality after infarction in the Cardiac Arrhythmia Suppression Trial and the failure of low-dose amiodarone to prevent sudden cardiac death in patients with a low left ventricular ejection fraction has shifted attention to other strategies, such as beta-adrenergic blocking agents, to prevent sudden cardiac death. Evidence suggesting that beta-adrenergic blocking agents might be useful, especially in patients with low left ventricular ejection fraction, is accumulating. Previous data from studies using beta-adrenergic blocking agents and the mechanisms by which beta-adrenergic blocking agents might be of value in preventing sudden cardiac death are reviewed. These considerations and the availability of new investigational beta-adrenergic blocking agents with vasodilator properties provide a new opportunity to test the hypothesis that beta-adrenergic blocking agents are useful in preventing sudden cardiac death, especially in patients with a low left ventricular ejection fraction.
More Related Videos
Related Concept Videos
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
01:17Antihypertensive Drugs: Action of β1 Blockers
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:22Heart Failure Drugs: β-Blockers
01:16Antianginal Drugs: Nitrates and β-Blockers
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...